Target Validation Information
Target ID T32060
Target Name 5-hydroxytryptamine 2A receptor
Target Type
Successful
Drug Potency against Target (R,S)-1-(5-methyl-1H-indol-1-yl)propan-2-amine Drug Info Ki = 794 nM
SR46349B Drug Info Ki = 1.26 nM [1]
Blonanserin Drug Info Ki = 5460 nM [2]
1,6-bis(4-phenylpiperazin-1-yl)hexane Drug Info Ki = 31 nM [3]
2-Piperazin-1-yl-phenol Drug Info Ki = 17200 nM [4]
1-(2,5-Dimethoxy-4-methyl-phenyl)-piperazine Drug Info Ki = 4710 nM [4]
Flibanserin Drug Info Ki = 49 nM
4-methoxy-9-aminomethyl-9,10-dihydroanthracene Drug Info Ki = 124 nM [5]
(E)-2-(4-fluorostyryl)-5-(phenylsulfinyl)pyridine Drug Info Ki = 7.7 nM [6]
GR-127935 Drug Info Ki = 42.7 nM [7]
3-(2-Pyrrolidin-1-yl-ethyl)-1H-indol-4-ol Drug Info Ki = 429 nM [8]
BARETTIN Drug Info Ki = 1930 nM [9]
N-methyl-4,4-diphenylbutan-1-amine Drug Info Ki = 754 nM [10]
Brolamfetamine Drug Info Ki = 13 nM [11]
QUIPAZINE Drug Info Ki = 794 nM [12]
1-(2,5-Dimethoxy-phenyl)-piperazine Drug Info Ki = 8430 nM [4]
1-Naphthalen-1-yl-piperazine Drug Info Ki = 18 nM [13]
1-(4-Bromo-2,5-dimethoxy-phenyl)-piperazine Drug Info Ki = 2430 nM [4]
2-(2-Amino-propyl)-5-bromo-4-methoxy-phenol Drug Info Ki = 210 nM [14]
2-(3-Methoxy-phenyl)-1-methyl-ethylamine Drug Info Ki = 7850 nM [14]
1,6-bis(4-(3-methoxyphenyl)piperazin-1-yl)hexane Drug Info Ki = 28 nM [3]
5,6-dichloro-3,4-dihydroquinazolin-2-amine Drug Info Ki = 434 nM [15]
5-MEO-DMT Drug Info IC50 = 9.53 nM [16]
(R)-1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine Drug Info IC50 = 0.46 nM [17]
11-Propionyloxy-N-n-propylnoraporphine Drug Info Ki = 109 nM [18]
APLYSINOPSIN Drug Info Ki = 598 nM
1192U90 Drug Info Ki = 3.3 nM [19]
2-methoxy-9-aminomethyl-9,10-dihydroanthracene Drug Info Ki = 1367 nM [5]
11-valeryloxynoraporphine Drug Info Ki = 92 nM [18]
11-Butyryloxy-N-n-propylnoraporphine Drug Info Ki = 56 nM [18]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Drug Info Ki < 1000 nM [20]
VOLINANSERIN Drug Info Ki = 0.36 nM [21]
ZOTEPINE Drug Info Ki = 2.7 nM [22]
4-(4-Fluoro-benzyl)-piperidine hydrochloride Drug Info Ki = 1100 nM [23]
6-chloro-N-(pyridin-3-yl)indoline-1-carboxamide Drug Info Ki = 794 nM
N,N-dimethyl-4,4-diphenylbutan-1-amine Drug Info Ki = 1151 nM [10]
N,N-dimethyl-2,2-diphenylethanamine Drug Info Ki = 7356 nM [10]
9-(2-aminoethyl)-9,10-dihydroanthracene Drug Info Ki = 480 nM [10]
4,4-Diphenylbutan-1-amine Drug Info Ki = 2589 nM [10]
Ocaperidone Drug Info Ki = 0.14 nM [24]
(R)-(+)-(4,5,6-trimethoxyindan-1-yl)methanamine Drug Info Ki = 69 nM [25]
(S)-(-)-(4,5,6-trimethoxyindan-1-yl)methanamine Drug Info Ki = 1120 nM [25]
LYSERGIC ACID DIETHYLAMIDE Drug Info Ki = 3.5 nM [25]
C-(5-bromo-4,7-dimethoxyindan-1-yl)methylamine Drug Info Ki = 47 nM [26]
[2-(6-Methoxy-indol-1-yl)-ethyl]-dimethyl-amine Drug Info Ki = 1040 nM [27]
9-(Aminomethyl)-9,10-dihydroanthracene Drug Info Ki = 20 nM [28]
CHLOROPHENYLPIPERAZINE Drug Info Ki = 48 nM [29]
RP-68303 Drug Info IC50 = 30 nM [30]
YM-348 Drug Info Ki = 13 nM [31]
VER-3323 Drug Info Ki = 351 nM [32]
2-(5-Methoxy-1H-indol-3-yl)-1-methyl-ethylamine Drug Info IC50 = 2 nM [16]
Ro-60-0175 Drug Info Ki = 39 nM [33]
1-(2-aminoethyl)-1H-indazol-6-ol Drug Info IC50 = 0.77 nM [16]
1-Butyl-3-(2-dimethylamino-ethyl)-1H-indol-4-ol Drug Info Ki = 310 nM [8]
3-(2-Dimethylamino-propyl)-1H-indol-4-ol Drug Info Ki = 982 nM [8]
3-(3-Dimethylamino-propyl)-1H-indol-4-ol Drug Info Ki = 588 nM [8]
(2S)-1-(5-fluoro-1H-indazol-1-yl)propan-2-amine Drug Info Ki = 89 nM [33]
7,8,9,10-tetrahydro-6H-furo-[2,3-g][3]benzazepine Drug Info Ki = 99 nM [31]
PRUVANSERIN Drug Info Ki = 0.48 nM [34]
2-(4-Bromo-2-methoxy-phenyl)-1-methyl-ethylamine Drug Info Ki = 4870 nM [14]
3-(1-Methyl-piperidin-4-yl)-2-phenyl-1H-indole Drug Info Ki = 7.8 nM [35]
2-Phenyl-3-(2-piperidin-1-yl-ethyl)-1H-indole Drug Info Ki = 2.7 nM [35]
3-(1-Benzyl-piperidin-4-yl)-2-phenyl-1H-indole Drug Info Ki = 28 nM [35]
2-(4-Methyl-piperazin-1-yl)-4-phenyl-pyrimidine Drug Info Ki = 2095 nM
TRYPTAMINE Drug Info Ki = 50 nM [36]
9-(N-benzylaminomethyl)-9,10-dihydroanthracene Drug Info Ki = 721 nM [37]
11-Heptanoyloxy-N-n-propylnoraporphine Drug Info Ki = 95 nM [18]
11-Hexanoyloxy-N-n-propylnoraporphine Drug Info Ki = 109 nM [18]
3-Dimethylaminomethyl-1-methyl-1H-indol-4-ol Drug Info Ki = 498 nM [8]
Iloperidone Drug Info KI = 11 nM [38]
VER-2692 Drug Info Ki = 31 nM [39]
1-Naphthalen-2-yl-piperazine Drug Info Ki = 70 nM [13]
SEROTONIN Drug Info Ki = 1258 nM [12]
3-Dimethylaminomethyl-1H-indol-4-ol Drug Info Ki = 923 nM [8]
(R)-3-(4-propylmorpholin-2-yl)phenol Drug Info Ki = 970 nM [40]
2-(4-Bromo-phenyl)-1-methyl-ethylamine Drug Info Ki = 4650 nM [14]
8-Methoxy-2-(4-methyl-piperazin-1-yl)-quinoline Drug Info Ki = 1200 nM [13]
PHENYLPIPERAZINE Drug Info Ki = 2100 nM [13]
3-(2-Amino-propyl)-1H-indol-5-ol Drug Info IC50 = 3.5 nM [16]
1,2,3,4-Tetrahydro-naphthalen-2-ylamine Drug Info Ki = 11100 nM [13]
Etisulergine Drug Info IC50 = 26 nM [41]
3-Amino-1-(2-amino-5-methoxy-phenyl)-propan-1-one Drug Info Ki = 8480 nM [4]
1-(2-Methoxy-phenyl)-piperazine Drug Info Ki = 3500 nM [4]
2-(2-Methoxy-phenyl)-1-methyl-ethylamine Drug Info Ki = 8130 nM [14]
(1-Phenethyl-piperidin-4-yl)-phenyl-methanone Drug Info Ki = 9.6 nM [22]
3-Naphthalen-1-yl-1-propyl-pyrrolidine Drug Info Ki = 113 nM
NELOTANSERIN Drug Info Ki = 0.51 nM [34]
SPIPERONE Drug Info Ki = 1 nM [42]
ALTANSERIN Drug Info Ki = 0.72 nM [21]
1,6-bis(4-(pyridin-2-yl)piperazin-1-yl)hexane Drug Info Ki = 45 nM [3]
CINANSERIN Drug Info Ki = 4 nM [36]
(R,S)-1-(6-fluoro-1H-indol-1-yl)propan-2-amine Drug Info Ki = 251 nM
FLUANISONE Drug Info Ki = 52 nM [43]
3-Naphthalen-1-yl-pyrrolidine Drug Info Ki = 40 nM
1-Propyl-3-(3-trifluoromethyl-phenyl)-pyrrolidine Drug Info Ki = 569 nM
1-Ethyl-4-(2-methoxy-phenyl)-piperazine Drug Info Ki = 3120 nM [44]
1-(3-(phenylthio)propyl)-4-m-tolylpiperazine Drug Info Ki = 13.6 nM [45]
MDL-11939 Drug Info Ki = 12.5 nM [23]
MDL-28161 Drug Info IC50 = 0.9 nM [23]
C-(9H-Thioxanthen-9-yl)-methylamine Drug Info Ki = 65 nM [28]
8-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline Drug Info Ki = 400 nM [46]
5-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline Drug Info Ki = 75 nM [46]
7-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline Drug Info Ki = 2200 nM [46]
2,2-Diphenyl-ethylamine Drug Info Ki = 5700 nM [28]
1,6-bis(4-m-tolylpiperazin-1-yl)hexane Drug Info Ki = 20 nM [3]
N,N-Dimethyl-3,3-diphenylpropan-1-amine Drug Info Ki = 1636 nM [10]
Pimavanserin Drug Info Ki = 8 nM [47]
6-bromoaplysinopsin Drug Info Ki = 2000 nM [48]
Adatanserin Drug Info Ki = 73 nM [49]
TIOSPIRONE Drug Info Ki = 0.58 nM [50]
ISOCLOZAPINE Drug Info IC50 = 12 nM [51]
N-(1-benzylpiperidine-4-yl)-2-naphthamide Drug Info Ki = 44 nM [52]
Racemic DOI Drug Info Ki = 19 nM [53]
N-(1-(4-nitrobenzyl)piperidin-4-yl)-2-naphthamide Drug Info Ki = 278 nM [52]
(R,S)-1-(5-bromo-1H-indol-1-yl)propan-2-amine Drug Info Ki = 159 nM
1-Butyl-4-(2-methoxy-phenyl)-piperazine Drug Info Ki = 2280 nM [44]
N-(1-(3-bromobenzyl)piperidin-4-yl)-2-naphthamide Drug Info Ki = 53 nM [52]
7-Chloro-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole Drug Info Ki = 80 nM [27]
8-Chloro-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole Drug Info Ki = 320 nM [27]
(2S)-1-(6-fluoro-1H-indazol-1-yl)propan-2-amine Drug Info Ki = 82 nM [33]
(E)-2-(4-fluorostyryl)-5-(phenylsulfonyl)pyridine Drug Info Ki = 7.4 nM [6]
PG-01037 Drug Info Ki = 62.4 nM [54]
2,5-dimethoxy-4-bromophenethylamine Drug Info Ki = 0.88 nM [26]
(R,S)-1-(5-chloro-1H-indol-1-yl)propan-2-amine Drug Info Ki = 200 nM
YM-992 Drug Info Ki = 21 nM [55]
1-methoxy-9-aminomethyl-9,10-dihydroanthracene Drug Info Ki = 1158 nM [5]
Lurasidone hydrochloride Drug Info Ki = 2.03 nM [56]
WAY-208466 Drug Info IC50 = 351 nM [57]
5-chloro-N-(pyridin-3-yl)indoline-1-carboxamide Drug Info Ki = 2512 nM
2-(piperazin-1-yl)-5,6,7,8-tetrahydroquinoline Drug Info Ki = 21 nM [58]
5-METHOXYTRYPTAMINE Drug Info Ki = 14 nM [36]
Racemic DOTFM Drug Info Ki = 33 nM [53]
VER-5593 Drug Info Ki = 53 nM [32]
1-(2,6-dimethoxy-4-methylphenyl)propan-2-amine Drug Info Ki = 351 nM [53]
1-(4-Bromo-2,5-difluorophenyl)-2-aminopropane Drug Info Ki = 2505 nM [53]
4-Benzyl-1-methyl-piperidine hydrochloride Drug Info Ki = 3870 nM [23]
PRUVANSERIN Drug Info Ki = 0.87 nM [59]
8-Methoxy-4,9-dihydro-3H-beta-carboline Drug Info Ki = 2550 nM [46]
2-(1H-indol-3-yl)-N,N-dimethylethanamine Drug Info Ki = 1636 nM [53]
N-3'-ethylaplysinopsin Drug Info Ki = 1700 nM [48]
C-(9H-Xanthen-9-yl)-methylamine Drug Info Ki = 170 nM [28]
1-(3-Trifluoromethyl-phenyl)-piperazine Drug Info Ki = 160 nM [4]
8-Methoxy-2-piperazin-1-yl-quinoline Drug Info Ki = 310 nM [13]
1-((S)-2-aminopropyl)-7-methyl-1H-indazol-6-ol Drug Info IC50 = 0.74 nM [16]
MAZAPERTINE Drug Info Ki = 165 nM [60]
4-(10H-Anthracen-9-ylidene)-1-methyl-piperidine Drug Info Ki = 0.7 nM [28]
5-Methoxy-4,9-dihydro-3H-beta-carboline Drug Info Ki = 500 nM [46]
9-(2-aminopropyl)-9,10-dihydroanthracene Drug Info Ki = 32 nM [10]
(R)-(-)-11-hydroxy-N-n-propylnoraporphine Drug Info Ki = 114 nM [18]
2-(9,10-dihydroanthracen-9-yl)-N-methylethanamine Drug Info Ki = 92 nM [10]
N-methyl-3,3-diphenylpropan-1-amine Drug Info Ki = 1498 nM [10]
1-(2-Methoxy-phenyl)-4-propyl-piperazine Drug Info Ki = 3290 nM [44]
3-(2-Dimethylamino-ethyl)-1H-indol-6-ol Drug Info Ki = 7600 nM [8]
[2-(4-Fluoro-1H-indol-3-yl)-ethyl]-dimethyl-amine Drug Info Ki = 335 nM [8]
DOM Drug Info Ki = 100 nM [53]
N-(1-(4-bromobenzyl)piperidin-4-yl)-2-naphthamide Drug Info Ki = 223 nM [52]
2-(3,5-dimethoxy-4-phenethoxyphenyl)ethanamine Drug Info Ki = 59 nM [53]
C-(5H-Dibenzo[a,d]cyclohepten-5-yl)-methylamine Drug Info Ki = 4125 nM [28]
N-(1-phenethylpiperidin-4-yl)-2-naphthamide Drug Info Ki = 42 nM [61]
TRYPTOLINE Drug Info Ki = 3000 nM [46]
SB-271046 Drug Info Ki = 1740 nM [62]
5-chloro-3,4-dihydroquinazolin-2-amine Drug Info Ki = 1164 nM [15]
2-Phenyl-3-piperidin-4-yl-1H-indole Drug Info Ki = 12.1 nM [35]
1-(10-Bromoanthracen-9-yl)-2-aminopropane Drug Info Ki = 313 nM [53]
1-(2,5-dimethoxyphenyl)propan-2-amine Drug Info Ki = 5200 nM [53]
1-((R)-2-aminopropyl)-1H-indazol-6-ol Drug Info IC50 = 2.08 nM [16]
6-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline Drug Info Ki = 1400 nM [46]
8-Bromo-4,9-dihydro-3H-beta-carboline Drug Info Ki = 115 nM [46]
5-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline Drug Info Ki = 80 nM [46]
3-(1-Phenethyl-piperidin-4-yl)-2-phenyl-1H-indole Drug Info Ki = 0.5 nM [35]
1-(4-ethyl-2,5-dimethoxyphenyl)propan-2-amine Drug Info Ki = 100 nM [53]
8-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline Drug Info Ki = 21 nM [46]
3-methoxy-9-aminomethyl-9,10-dihydroanthracene Drug Info Ki = 7.5 nM [5]
(2S)-1-(1H-furo[2,3-g]indazol-1-yl)propan-2-amine Drug Info Ki = 0.78 nM [33]
PHENETHYLAMINE Drug Info Ki = 16820 nM [28]
1,2,3,4-Tetrahydro-pyrazino[1,2-a]indole Drug Info Ki = 635 nM [27]
7,8,9,10-tetrahydro-6H-furo-[3,2-g][3]benzazepine Drug Info Ki = 46 nM [31]
1,6-bis(4-(3-chlorophenyl)piperazin-1-yl)hexane Drug Info Ki = 98 nM [3]
N-(1-(1-phenylethyl)piperidin-4-yl)-1-naphthamide Drug Info Ki = 248 nM [61]
PSILOCIN Drug Info Ki = 323 nM [53]
MESCALINE Drug Info Ki = 5500 nM [53]
N-(1-phenethylpiperidin-4-yl)-1-naphthamide Drug Info Ki = 543 nM [61]
N-(1-(4-phenylbutyl)piperidin-4-yl)-2-naphthamide Drug Info Ki = 213 nM [61]
N-(1-(3-bromobenzyl)piperidin-4-yl)-1-naphthamide Drug Info Ki = 462 nM [52]
(2-Indol-1-yl-ethyl)-dimethyl-amine Drug Info Ki = 650 nM [27]
N-(1-(4-phenylbutyl)piperidin-4-yl)-1-naphthamide Drug Info Ki = 487 nM [61]
N-(1-(1-phenylethyl)piperidin-4-yl)-2-naphthamide Drug Info Ki = 110 nM [61]
6-Chloro-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole Drug Info Ki = 330 nM [27]
VER-5384 Drug Info Ki = 112 nM [32]
1-((S)-2-aminopropyl)-1H-indazol-6-ol Drug Info IC50 = 0.58 nM [16]
A-80426 Drug Info Ki = 144 nM [63]
(+/-)-nantenine Drug Info Ki = 832 nM [64]
1-((S)-2-aminopropyl)-7-iodo-1H-indazol-6-ol Drug Info IC50 = 1.68 nM [16]
(2S)-1-(6-methoxy-1H-indazol-1-yl)propan-2-amine Drug Info IC50 = 1.91 nM [16]
3-(2-Dimethylamino-ethyl)-1-methyl-1H-indol-4-ol Drug Info Ki = 900 nM [8]
1-((S)-2-aminopropyl)-7-fluoro-1H-indazol-6-ol Drug Info IC50 = 0.73 nM [16]
3-(2-Dimethylamino-ethyl)-2-methyl-1H-indol-4-ol Drug Info Ki = 122 nM [8]
1-((S)-2-aminopropyl)-7-chloro-1H-indazol-6-ol Drug Info IC50 = 0.54 nM [16]
6,7-dichloro-2,3,4,5-tetrahydro-1H-3-benzazepine Drug Info Ki = 93 nM [31]
(S)-1-(5,6-difluoro-1H-indol-1-yl)propan-2-amine Drug Info Ki = 100 nM
1-Methyl-1,3-dihydro-indol-2-one Drug Info Ki = 25 nM [65]
(R,S)-1-(5-fluoro-1H-indol-1-yl)propan-2-amine Drug Info Ki = 159 nM
References
REF 1(1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists. J Pharmacol Exp Ther. 1995 Apr;273(1):101-12.
REF 2Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. J Pharmacol Exp Ther. 1993 Jan;264(1):158-65.
REF 3J Med Chem. 2010 Jun 24;53(12):4803-7.Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors.
REF 4J Med Chem. 1986 May;29(5):630-4.Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents.
REF 5Bioorg Med Chem Lett. 2008 Oct 1;18(19):5268-71. Epub 2008 Aug 22.Methoxy-substituted 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives exhibit differential binding affinities at the 5-HT(2A) receptor.
REF 6Bioorg Med Chem Lett. 2007 May 1;17(9):2643-8. Epub 2007 Feb 2.2,5-Disubstituted pyridines: the discovery of a novel series of 5-HT2A ligands.
REF 7Bioorg Med Chem Lett. 2005 Nov 1;15(21):4786-9.Synthesis of potent and selective serotonin 5-HT1B receptor ligands.
REF 8Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.
REF 9J Nat Prod. 2006 Oct;69(10):1421-4.Brominated cyclodipeptides from the marine sponge Geodia barretti as selective 5-HT ligands.
REF 10Bioorg Med Chem. 2009 Sep 15;17(18):6496-504. Epub 2009 Aug 13.Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.
REF 11Bioorg Med Chem. 2008 Jun 1;16(11):6242-51. Epub 2008 May 6.'Hybrid' benzofuran-benzopyran congeners as rigid analogs of hallucinogenic phenethylamines.
REF 12J Med Chem. 2009 Nov 12;52(21):6946-50.Novel, potent, and selective quinoxaline-based 5-HT(3) receptor ligands. 1. Further structure-activity relationships and pharmacological characterization.
REF 13J Med Chem. 1986 Nov;29(11):2375-80.5-HT1 and 5-HT2 binding characteristics of some quipazine analogues.
REF 14J Med Chem. 1986 Feb;29(2):194-9.5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues.
REF 15Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. Epub 2007 Oct 30.Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation.
REF 16J Med Chem. 2006 Jan 12;49(1):318-28.1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity.
REF 17Bioorg Med Chem Lett. 2007 Jun 1;17(11):2998-3002. Epub 2007 Mar 25.Novel benzodifuran analogs as potent 5-HT2A receptor agonists with ocular hypotensive activity.
REF 18Bioorg Med Chem. 2008 Sep 15;16(18):8335-8. Epub 2008 Aug 28.N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands.
REF 19Synthesis and evaluation of heterocyclic carboxamides as potential antipsychotic agents. J Med Chem. 1996 Nov 22;39(24):4692-703.
REF 20J Med Chem. 2010 Sep 9;53(17):6386-97.Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential.
REF 21Bioorg Med Chem. 2009 Apr 15;17(8):2989-3002. Epub 2009 Mar 14.Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET.
REF 22J Med Chem. 2001 Feb 15;44(4):477-501.Current and novel approaches to the drug treatment of schizophrenia.
REF 23J Med Chem. 1992 Dec 25;35(26):4903-10.Ketanserin analogues: structure-affinity relationships for 5-HT2 and 5-HT1C serotonin receptor binding.
REF 24In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol Pharmacol. 1992 Mar;41(3):494-508.
REF 25J Med Chem. 2006 Jul 13;49(14):4269-74.C-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor.
REF 26J Med Chem. 2006 Sep 21;49(19):5794-803.1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists.
REF 27Bioorg Med Chem Lett. 2002 Jan 21;12(2):155-8.Evaluation of isotryptamine derivatives at 5-HT(2) serotonin receptors.
REF 28Bioorg Med Chem Lett. 2001 Feb 26;11(4):563-6.Exploring the relationship between binding modes of 9-(aminomethyl)-9,10-dihydroanthracene and cyproheptadine analogues at the 5-HT2A serotonin receptor.
REF 29Bioorg Med Chem Lett. 2010 Feb 1;20(3):1128-33. Epub 2009 Dec 6.Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.
REF 30J Med Chem. 1993 Apr 30;36(9):1194-202.New indole derivatives as potent and selective serotonin uptake inhibitors.
REF 31Bioorg Med Chem. 2008 Mar 15;16(6):3309-20. Epub 2007 Dec 8.Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists.
REF 32Bioorg Med Chem Lett. 2004 May 3;14(9):2367-70.Indoline derivatives as 5-HT(2C) receptor agonists.
REF 33Bioorg Med Chem. 2008 Feb 15;16(4):1966-82. Epub 2007 Nov 4.Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists.
REF 34J Med Chem. 2010 Aug 12;53(15):5696-706.Synthesis and in vivo evaluation of phenethylpiperazine amides: selective 5-hydroxytryptamine(2A) receptor antagonists for the treatment of insomnia.
REF 35Bioorg Med Chem Lett. 2000 Dec 18;10(24):2701-3.3-(4-Piperidinyl)- and 3-(8-aza-bicyclo[3.2.1]oct-3-yl)-2-phenyl-1H-indoles as bioavailable h5-HT2A antagonists.
REF 36J Med Chem. 1987 Jan;30(1):1-12.Central serotonin receptors as targets for drug research.
REF 37Bioorg Med Chem Lett. 2010 Feb 1;20(3):935-8. Epub 2009 Dec 23.9-Aminomethyl-9,10-dihydroanthracene (AMDA) analogs as structural probes for steric tolerance in 5-HT2A and H1 receptor binding sites.
REF 38The pharmacological profile of iloperidone, a novel atypical antipsychotic agent. J Pharmacol Exp Ther. 1995 Sep;274(3):1404-13.
REF 39Bioorg Med Chem Lett. 2006 Feb;16(3):677-80. Epub 2005 Oct 27.Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.
REF 40Bioorg Med Chem Lett. 2007 Dec 15;17(24):6691-6. Epub 2007 Oct 22.Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route.
REF 41J Med Chem. 1985 Oct;28(10):1540-2.Resolution and absolute configuration of the potent dopamine agonist N,N-diethyl-N'-[(3 alpha, 4a alpha, 10a beta)-1,2,3,4,4a,5,10,10a- -octahydro-6-hydroxy-1-propyl-3-benzo[g]quinolinyl]sulfamide.
REF 42J Nat Prod. 1997 Jun;60(6):651-3.Activity of Parthenolide at 5HT2A receptors.
REF 43J Med Chem. 1987 Nov;30(11):2099-104.2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 1.
REF 44J Med Chem. 1994 Aug 19;37(17):2754-60.Structure-activity relationship studies of central nervous system agents. 13. 4-[3-(Benzotriazol-1-yl)propyl]-1-(2-methoxyphenyl)piperazine, a new putative 5-HT1A receptor antagonist, and its analogs.
REF 45Bioorg Med Chem Lett. 2007 Mar 15;17(6):1708-12. Epub 2006 Dec 23.Synthesis and QSAR studies on hypotensive 1-[3-(4-substituted phenylthio) propyl]-4-(substituted phenyl) piperazines.
REF 46Bioorg Med Chem Lett. 2003 Dec 15;13(24):4421-5.Binding of beta-carbolines at 5-HT(2) serotonin receptors.
REF 475-HT(2A) inverse-agonists for the treatment of insomnia. Curr Top Med Chem. 2008;8(11):969-76.
REF 48J Nat Prod. 2002 Apr;65(4):476-80.New antiinfective and human 5-HT2 receptor binding natural and semisynthetic compounds from the Jamaican sponge Smenospongia aurea.
REF 49Synthesis and SAR of adatanserin: novel adamantyl aryl- and heteroarylpiperazines with dual serotonin 5-HT(1A) and 5-HT(2) activity as potential anxiolytic and antidepressant agents. J Med Chem. 1999Dec 16;42(25):5077-94.
REF 50J Med Chem. 1996 Jan 5;39(1):143-8.3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents.
REF 51J Med Chem. 1997 Dec 5;40(25):4146-53.Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: identification of a novel atypical neuroleptic.
REF 52Bioorg Med Chem Lett. 2007 Mar 15;17(6):1570-4. Epub 2007 Jan 8.Synthesis and in vitro binding studies of substituted piperidine naphthamides. Part II: Influence of the substitution on the benzyl moiety on the affinity for D2L, D4.2, and 5-HT2A receptors.
REF 53Bioorg Med Chem. 2008 Apr 15;16(8):4661-9. Epub 2008 Feb 14.The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands.
REF 54J Med Chem. 2007 Aug 23;50(17):4135-46. Epub 2007 Aug 2.Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents.
REF 55Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century--a medicinal chemistry survey. Curr Top Med Chem. 2006;6(17):1801-23.
REF 56Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmacol. 2007 Oct 31;572(2-3):160-70. Epub 2007 Jul 10.
REF 57Bioorg Med Chem. 2009 Jul 15;17(14):5153-63. Epub 2009 May 29.Novel 1-aminoethyl-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines are potent 5-HT(6) agonists.
REF 58Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. Epub 2009 Oct 30.Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.
REF 59Bioorg Med Chem Lett. 2006 Jun 15;16(12):3201-4. Epub 2006 May 2.A new class of selective, non-basic 5-HT2A receptor antagonists.
REF 60J Med Chem. 1994 Apr 15;37(8):1060-2.A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects.
REF 61Bioorg Med Chem Lett. 2007 Mar 15;17(6):1565-9. Epub 2007 Jan 8.Synthesis and in vitro binding studies of substituted piperidine naphthamides. Part I: Influence of the substitution on the basic nitrogen and the position of the amide on the affinity for D2L, D4.2, and 5-HT2A receptors.
REF 62Bioorg Med Chem Lett. 2008 Jan 15;18(2):738-43. Epub 2007 Nov 17.Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists.
REF 63J Med Chem. 2005 Oct 20;48(21):6523-43.Designed multiple ligands. An emerging drug discovery paradigm.
REF 64Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31. Epub 2009 Nov 20.Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine.
REF 65Bioorg Med Chem Lett. 2001 May 7;11(9):1229-31.Influence of the terminal amide fragment geometry in some 3-arylideneindolin-2(1H)-ones on their 5-HT1A/5-HT2A receptor activity.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.